Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes

Table 3 Harrell’s c-statistics, NRI, IDI for risk of major outcomes according to traditional risk factors without and with history of microvascular or macrovascular disease at baseline

Risk of all-cause mortality		P
C-statistic (95% CI) for basic model	0.704 (0.693 to 0.716)
Change in C-statistic (95% CI) for basic model + microvascular disease	0.005 (0.002 to 0.008)	0.02
Change in C-statistic (95% CI) for basic model + macrovascular disease	0.005 (0.002 to 0.007)	<0.0001
Change in C-statistic (95% CI) for basic model + microvascular disease + macrovascular disease	0.011 (0.007 to 0.014)	<0.0001
IDI (95% CI)	0.013 (0.010 to 0.016)	<0.001
Continuous NRI (95% CI)	0.275 (0.227 to 0.325)	<0.001
Categorical NRI (95% CI)	0.021 (0.011 to 0.032)	<0.001
Risk of major macrovascular events (MACE)
C-statistic (95% CI) for basic model	0.648 (0.631 to 0.665)
Change in C-statistic (95% CI) for basic model + microvascular disease	0.009 (0.003 to 0.014)	0.002
IDI (95% CI)	0.008 (0.006 to 0.010)	<0.001
Continuous NRI (95% CI)	0.120 (0.073 to 0.167)	<0.001
Categorical NRI (95% CI)	0.011 (0.001 to 0.020)	0.02
Risk of major clinical microvascular events
C-statistic (95% CI) for basic model	0.664 (0.639 to 0.689)
Change in C-statistic (95% CI) for basic model + macrovascular disease	0.004 (−0.003 to 0.011)	0.25
IDI (95% CI)	0.002 (0.001 to 0.002)	<0.001
Continuous NRI (95% CI)	0.211 (0.112 to 0.305)	<0.001
Categorical NRI (95% CI)	0.041 (0.002 to 0.087)	0.03

Basic model: sex, age, region of origin, BMI, duration of diabetes, HbA1c, systolic blood pressure, antihypertensive treatment, eGFR and its square, urinary albumin-creatinine ratio (for major clinical microvascular events), LDL- and HDL-cholesterol, history of ever smoking, and study allocations. IDI (integrated discrimination improvement) and NRI (net reclassification improvement) tests performed for basic model plus history of microvascular (risk of MACE), macrovascular disease (risk of major clinical microvascular events) or both (risk of all-cause mortality) at baseline, compared to basic model alone. Analyses performed in patients free of baseline history of microvascular disease (risk of major clinical microvascular events), or free of macrovascular disease (risk of MACE)

ISSN: 1475-2840